Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02822482
Other study ID # UC-0130/1507
Secondary ID 2015-004340-19
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date June 2016
Est. completion date October 9, 2019

Study information

Verified date March 2021
Source UNICANCER
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study consists of two distinct and sequential parts: - A Phase Ib aimed at determining the MTD (Maximum Tolerated Dose) of the combination (copanlisib/cetuximab) and the RP2D - A Phase II aimed at evaluating the efficacy of the combination at the RP2D (Recommended Phase 2 Dose) All patients will be treated with the Copanlisib, a selective PI3KCA inhibitor, in association with Cetuximab.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date October 9, 2019
Est. primary completion date October 9, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients with R/M HNSCC (oropharynx, oral cavity, hypopharynx and larynx), histologically or cytologically confirmed, not amenable to curative treatment with surgery and/or chemotherapy and/or radiotherapy (Stage III/IV) 2. Adult men and women = 18 years 3. Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 4. Patients with tumor harboring a PI3K mutation/amplification and/or a PTEN loss 5. Patients with a radiologic documented progression or relapse after cetuximab therapy (patients could have either received combination platinum doublet with cetuximab or cetuximab after platinum doublet) 6. Patients with prior platinum based therapy, unless contraindicated 7. Patients with at least one measurable lesion assessed by Magnetic Resonance Imaging (MRI) or a computerized tomography scanner (CT-scan) according to RECIST v1.1. Patients must have clinically and/or radiographically documented measurable disease. At least one site of disease must be unidimensionally measurable as follows - CT-scan, physical exam = 10 mm - Lymph node short axis = 15 mm Tumor measurements must be performed within 28 days prior to starting study drug 8. Women of childbearing potential and men must agree to use adequate contraception when sexually active. This applies since signing of the informed consent form and up to 12 months (for women of child bearing potential) and 6 months (for fertile men) after the last study drug administration (Copanlisib). Highly effective contraception methods are detailed in section 7.2 9. Women of childbearing age or sexually active female patients with reproductive potential must have a negative pregnancy test (serum or urine within the 7 days prior to starting study drug) 10. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses 11. Patients with social insurance coverage 12. Glomerular filtration rate (GFR) = 40 mL/min/1.73 m² according to the Modification of Diet in Renal Disease (MDRD) abbreviated formula (within 7 days prior to starting study drug). If not on target, this evaluation may be repeated once after at least 24 hours either according to the MDRD abbreviated formula or by 24 hour sampling. If the later result is within acceptable range, it may be used to fulfill the inclusion criteria instead Exclusion Criteria: 1. Patients previously treated with PI3K and/or mTOR inhibitors 2. Patients with anticancer therapy (radiotherapy, immunotherapy, chemotherapy, etc.) within 28 days or investigational treatment within 28 days prior to the initiation of study drug treatment, unless evidence of progression since last treatment 3. Patients currently using other approved or investigational anti-neoplasic agent 4. Patients with uncontrolled arterial hypertension despite optimal medical management, Congestive heart failure > New York Heart Association (NYHA) class 2, Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before start of test drug No active cardiac disease including any of the following: left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Gated Acquisition (MUGA) scan or echocardiogram (ECHO) and QTc > 470 ms on screening ECG 5. Patients with uncontrolled diabetes mellitus (patients with controlled Type I or II diabetes mellitus will be eligible but only into the phase II of the study and only if fasting HbA1c = 8.5% at screening) 6. Patients with a history of Human Immunodeficiency Virus (HIV) Hepatitis B (HBV) or hepatitis C (HCV) infection. All patients must be screened for HIV, HBV and HCV up to 28 days prior to first dosing using the routine virus laboratorial panel. Patients who are positive for HBs Ag or HBc Ab will be eligible if they are negative for HBV-DNA. Patients who are positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA 7. Patients with active uncontrolled or symptomatic central nervous system (CNS) metastases. Patients are eligible if their disease is controlled at least 30 days on corticosteroids prior to starting study drug 8. Patients with major surgery within 28 days, or open biopsy within 7 days, prior to starting study drug. Patients must have recovered from major side effects of the surgery 9. Patients receiving any medications or substances that are inhibitors or inducers of CYP3A4 are ineligible. Copanlisib is primarily metabolized by CYP3A4. Therefore concomitant use of strong inhibitors of CyP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir), and inducers of CYP3A (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, st. John's Wort) are not permitted from Day -14 of Cycle 1 until the Safety follow up visit 10. Patients with altered hematopoietic or organ function, as indicated by the following criteria (assessed within 7 days prior the first dosing): - Absolute granulocytes < 1.0 x 10?/L - Platelets < 75 x 10?/L - ALAT/ASAT > 2.5 x ULN in the absence of or > 5 x ULN in the presence of liver metastases - Bilirubin > 1.5 x ULN (except Gilbert Syndrome: < 3.0 mg/dL) - Creatinine clearance < 60 mL/min (measured or calculated by Cockcroft and Gault formula) or serum creatinine > 1.0 x ULN - Lipase > 1.5 x ULN - INR and PTT > 1.5 x ULN 11. Patients with a history of hypersensitivity to other monoclonal antibodies or to the active or inactive excipients of study drug 12. Known drug or alcohol abuse 13. Known or underlying medical condition that, in the investigator's opinion, would make the administration of study drug hazardous to the patient or obscure the interpretation of toxicity determination or adverse events 14. History of uncontrolled seizures, seizure disorder requiring medication, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake 15. Unwillingness to give written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the study 16. Individuals deprived of liberty or placed under the authority of a tutor 17. Previous or concurrent history of malignancies within 5 years prior to study treatment except for curatively treated: - Cervical carcinoma in situ - Non-melanoma skin cancer - Superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria]) - Localized prostate cancer 18. Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event = CTCAE Grade 3 within 4 weeks prior to the start of study medication 19. Proteinuria of = CTCAE Grade 3 as assessed by a 24h protein quantification or estimated by urine protein-creatinine ratio > 3.5 on a random urine sample 20. History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator) 21. Concurrent diagnosis of pheochromocytoma 22. Pregnant or breast-feeding patients. Women of childbearing potential must have a serum pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment 23. Unresolved toxicity higher than CTCAE Grade 1 attributed to any prior therapy/procedure, excluding alopecia 24. Ongoing immunosuppressive therapy 25. Blood or platelets transfusion less than 7 days before starting treatment 26. Myeloid growth factors within 14 days prior to treatment 27. Systemic continuous corticosteroid therapy at a daily dose higher than 15 mg prednisone or equivalent is not allowed. Previous corticosteroid therapy must be stopped or reduced to the allowed dose 7 days before performing the screening CT scan/MRI, whichever is performed first, and again prior to the first study drug administration. If a patient is on chronic corticosteroid therapy, corticosteroids should be de-escalated to the maximum allowed dose after the patient has signed the IC. Patients may be using topical or inhaled corticosteroids 28. History of having received an allogeneic bone marrow or organ transplant 29. Anti-arrhythmic therapy (beta blockers or digoxin are permitted)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Copanlisib
Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
Cetuximab
Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.

Locations

Country Name City State
France Institut de Cancérologie de l'Ouest Angers
France Centre Georges François Leclerc Dijon
France Centre Oscar Lambret Lille
France Centre Léon Bérard Lyon
France Institut de Cancérologie de Lorraine Nancy
France Centre Antoine Lacassagne Nice
France Institut Curie Paris

Sponsors (1)

Lead Sponsor Collaborator
UNICANCER

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase Ib (dose escalation phase): to determine the Maximal Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of Copanlisib in association with Cetuximab Determination of the MTD will be based on the occurence of Dose Limiting Toxicities during Cycle 1. 1 month
Primary Phase II (expansion phase) : to assess the efficacy of the combination (Copanlisib + Cetuximab) at the RP2D. Efficacy of the combination will be assessed through Progression Free Survival at week 16. 16 weeks
Secondary Efficacy of the combination Objective Response Rate (ORR) using RECIST 1.1 criteria Through the study completion with an average of 10 months
Secondary Efficacy of the combination Overall Survival (OS) Through the study completion with an average of 10 months
Secondary Adverse Events (NCI CTCAE v4.0) All Adverse Events (NCI CTCAE v4.0), related or not related to Copanlisib or Cetuximab, will be collected in the Case Report Form in order to picture the safety profile of the association. Up to 15 cycles
Secondary Copanlisib Maximum Plasma Concentration [Cmax] For patients enrolled in the phase Ib (dose escalation phase) pharmacokinetic samples (blood) will be collected at Cycle 1 Day 1 and Cycle 1 Day 15. There will be 5 samples per day: pre-infusion, end of infusion, 2 hours, 8 hours and 24 hours after the start of Copanlisib infusion. First Month (at Day 1 and Day 15)
Secondary Area Under the Curve [AUC] for Copanlisib pharmacokinetic For patients enrolled in the phase Ib (dose escalation phase) pharmacokinetic samples (blood) will be collected at Cycle 1 Day 1 and Cycle 1 Day 15. There will be 5 samples per day: pre-infusion, end of infusion, 2 hours, 8 hours and 24 hours after the start of Copanlisib infusion. First Month (at Day 1 and Day 15)
Secondary Mutational profile of circulating tumoral DNA (ctDNA) For patients enrolled in the phase II (dose escalation phase) blood samples will be collected at baseline, C1D1, C1D15, 8 weeks, Disease progression or end of treatment whichever comes first. through the study duration: baseline, C1D1, C1D15, 8 weeks, disease progression
See also
  Status Clinical Trial Phase
Completed NCT02113878 - Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck Phase 1
Active, not recruiting NCT03291002 - Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC Phase 1
Terminated NCT02277184 - Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 1
Completed NCT01080066 - A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN) N/A
Completed NCT02585973 - Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC Phase 1
Completed NCT01836029 - Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Phase 2
Active, not recruiting NCT03715946 - Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer Phase 2
Active, not recruiting NCT03088059 - Biomarker-based Study in R/M SCCHN Phase 2
Recruiting NCT06003231 - A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Phase 2
Terminated NCT02438995 - Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck Phase 1
Completed NCT02242916 - State of the Art Photon Therapy Versus Particle Therapy for Recurrent Head & Neck Tumors; a Planning Study N/A
Recruiting NCT01876693 - A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy N/A
Terminated NCT02655068 - Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer Phase 3
Active, not recruiting NCT03509012 - Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT02296684 - Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT03799744 - Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma Phase 1
Completed NCT03109158 - NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Phase 1/Phase 2
Recruiting NCT03485209 - Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Phase 2
Completed NCT01307267 - A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Phase 1
Completed NCT02101034 - PD 0332991 and Cetuximab in Patients With Incurable SCCHN Phase 1/Phase 2